Drugs / CS0159
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07429331 | Mar 2026 | — | Cascade Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT06888115 | Mar → May 2025 | primary biliary cholangitis | Cascade Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT06098027 | Oct → Nov 2023 | primary biliary cholangitis | Cascade Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05624294 | Dec 2022 → Mar 2023 | primary biliary cholangitis | Cascade Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05082779 | Oct 2021 → Sep 2022 | primary sclerosing cholangitis | Cascade Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05896124 | Aug 2023 → Dec 2025 overdue | primary biliary cholangitis | Cascade Pharmaceuticals, Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05896137 | Aug 2023 → Nov 2025 overdue | primary sclerosing cholangitis | Cascade Pharmaceuticals, Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05591079 | Feb → Nov 2023 | metabolic dysfunction-associated steatohepatitis | Cascade Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07282353 | Dec 2025 → Dec 2027 expected | primary biliary cholangitis | Cascade Pharmaceuticals, Inc | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| — | NCT07570810 Comparator | Jun → Nov 2026 expected | NAFLD1, obesity disorder, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT06492330 Comparator | Jul 2024 → Feb 2025 | metabolic dysfunction-associated steatohepatitis, obesity disorder, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS0159 | “CS0159 (Linafexor)” NCT05591079 ↗ |
| Known as | Linafexor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05591079 ↗ |
| Action | Activate | “A novel, selective farnesoid X receptor (FXR) agonist.” NCT07429331 ↗ |
| Route | Oral | “Oral QD” NCT05591079 ↗ |